This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015;11(6):905-7.

doi: 10.2217/fon.15.6.

Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer

Mehmet Ali Nahit Şendur¹, Sercan Aksoy, Muhammed Bülent Akıncı, Nuriye Ozdemir, Didem Şener Dede, Kadri Altundag, Nurullah Zengin, Bülent Yalçın

Affiliations

PMID: 25760972
DOI: 10.2217/fon.15.6

Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer

Mehmet Ali Nahit Şendur et al. Future Oncol. 2015.

. 2015;11(6):905-7.

doi: 10.2217/fon.15.6.

Authors

Mehmet Ali Nahit Şendur¹, Sercan Aksoy, Muhammed Bülent Akıncı, Nuriye Ozdemir, Didem Şener Dede, Kadri Altundag, Nurullah Zengin, Bülent Yalçın

Affiliation

¹ Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, 06100 Sihhiye, Ankara, Turkey.

PMID: 25760972
DOI: 10.2217/fon.15.6

No abstract available

Keywords: aromatase inhibitors; exemestane; ovarian suppression; premenopausal breast cancer; tamoxifen.

PubMed Disclaimer

Similar articles

Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Bertelli G, Gangadhara S. Bertelli G, et al. Expert Opin Pharmacother. 2010 Aug;11(11):1933-42. doi: 10.1517/14656566.2010.495945. Expert Opin Pharmacother. 2010. PMID: 20569090 Review.
Intergroup Exemestane Study mature analysis: overall survival data.
Jassem J; International Exemestane Study Group. Jassem J, et al. Anticancer Drugs. 2008 Feb;19 Suppl 1:S3-7. doi: 10.1097/01.cad.0000277608.23376.bc. Anticancer Drugs. 2008. PMID: 18340242
Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Figg WD 2nd, Cook K, Clarke R. Figg WD 2nd, et al. Cancer Biol Ther. 2014;15(12):1586-7. doi: 10.4161/15384047.2014.972783. Cancer Biol Ther. 2014. PMID: 25535893 Free PMC article. Review.
Are SOFT and TEXT results practice changing and how?
Pagani O, Regan MM, Francis PA. Pagani O, et al. Breast. 2016 Jun;27:122-5. doi: 10.1016/j.breast.2016.02.008. Epub 2016 Apr 22. Breast. 2016. PMID: 27107153
[ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].
Perrone F. Perrone F. Tumori. 2006 Jul-Aug;92(4):suppl 1-9. Tumori. 2006. PMID: 17036536 Review. Italian. No abstract available.

See all similar articles

Cited by

Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
Pistelli M, Mora AD, Ballatore Z, Berardi R. Pistelli M, et al. Curr Oncol. 2018 Apr;25(2):e168-e175. doi: 10.3747/co.25.3735. Epub 2018 Apr 30. Curr Oncol. 2018. PMID: 29719441 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information